Mark Johnson to Mammary Neoplasms, Experimental
This is a "connection" page, showing publications Mark Johnson has written about Mammary Neoplasms, Experimental.
Connection Strength
0.215
-
Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR, Merlino G, Dickson RB, Johnson MD, Green JE. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008 Sep 11; 27(40):5373-84.
Score: 0.073
-
Jamerson MH, Johnson MD, Dickson RB. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene. 2000 Feb 21; 19(8):1065-71.
Score: 0.041
-
McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene. 1998 May 28; 16(21):2755-66.
Score: 0.036
-
Amundadottir LT, Nass SJ, Berchem GJ, Johnson MD, Dickson RB. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene. 1996 Aug 15; 13(4):757-65.
Score: 0.032
-
Low JA, Johnson MD, Bone EA, Dickson RB. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res. 1996 Jul; 2(7):1207-14.
Score: 0.032